Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

AIDS-Related Complex

Carter, W.A. et al., Cooley, T.P. et al., Broder, S. et al., Gerna, G. et al., Kopelman, R.G. et al., et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AIDS-Related Complex

We conducted a Phase I open-label trial of 2',3'-dideoxyinosine (ddI) for the treatment of the acquired immunodeficiency syndrome (AIDS) and severe AIDS-related complex [1].
We conclude that ddI has antiretroviral activity in patients with AIDS or AIDS-related complex and that the toxicity of ddI differs from that of zidovudine [1].
A significant reduction was found in patients with AIDS (185 +/- 93 CR1/cell), AIDS-related complex, and generalized lymphadenopathy, whereas healthy male homosexuals or normal controls had 434 +/- 193 and 509 +/- 140 CR1/cell, respectively (P less than 0.001) [2].
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo [3].
Suramin was given to ten outpatients with acquired immunodeficiency syndrome (AIDS) presenting as Kaposi's sarcoma (KS) or as an AIDS-related complex (ARC) [3].

High impact information on AIDS-Related Complex

It was detected in 11 of 48 patients (23 percent) with asymptomatic infection, 32 of 71 (45 percent) in Class IVa of the Centers for Disease Control (those with AIDS-related complex), and 75 of 92 (82 percent) in Class IVc (those with AIDS) (P less than 0.01) [4].
Examination of six patients with an "AIDS-related complex" revealed significantly reduced numbers of Langerhans' cells per square millimeter; this reduction was more pronounced in staining for Ia antigen (306 +/- 69) than in staining for ATPase activity (517 +/- 101) [5].
Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex [6].
10 patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or lymphadenopathy syndrome (LAS) were given 200-250 mg ampligen, a mismatched double-stranded (ds) RNA with in-vitro antiviral activity against human immunodeficiency virus (HIV), twice a week for up to 18 weeks, without side-effects or toxicity [7].
Sera were tested in 263 subjects who had AIDS or AIDS-related complex or were at-risk or not-at-risk of AIDS from the USA, Africa, and Asia/Oceania [8].

Chemical compound and disease context of AIDS-Related Complex

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex [9].
Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex [7].
Urinary neopterin and biopterin levels in patients with AIDS and AIDS-related complex [10].
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex [11].
CONCLUSIONS: Oral ribavirin, 600 mg daily, was well tolerated and safe in the patients with severe AIDS and the AIDS-related complex [12].

Biological context of AIDS-Related Complex

STUDY OBJECTIVE: To evaluate the safety and pharmacokinetics of recombinant, soluble human CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex [13].
There is considerable interest in the potential of human immunodeficiency virus type 1 (HIV-1) to develop drug resistance, especially as 3'-azido-3'-deoxythymidine (Retrovir) is now in widespread clinical use to treat people with AIDS and AIDS-related complex (ARC) [14].
Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS [15].
Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex [16].
Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex [17].

Anatomical context of AIDS-Related Complex

Patients were divided into three groups: (1) asymptomatic subjects with greater than 400 x 10(6)/l CD4 lymphocytes (n = 30); (2) asymptomatic subjects with less than 400 x 10(6)/l of CD4 lymphocytes and zidovudine (n = 20), and (3) AIDS-related complex (ARC)/AIDS patients on zidovudine (n = 32) [18].
In contrast to their HIV-infected parents, children with AIDS or AIDS-related complex were less likely to have decreased numbers of circulating T4 cells, and their sera recognized fewer HIV polypeptides on western blots [19].
A 26-year-old man with AIDS-related complex (ARC) was treated with high-dose busulphan and cyclophosphamide, followed by allogeneic bone marrow transplantation [20].
Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study [21].
Using the erythrocyte transketolase activation assay, we now report biochemical evidence of thiamine deficiency in 9/39 (23%) of patients with AIDS or AIDS-related complex [22].

Gene context of AIDS-Related Complex

Relative to normal cells, the expression of AFP and IL-2 receptors appeared considerably reduced in AIDS-related complex (ARC) and AIDS patients [23].
Vif antibodies were detected only in a low percentage in early stages of disease, but their prevalence increased to 36% and 72% with progression of disease to AIDS-related complex and AIDS [24].
Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC) [25].
Relatively low dose treatment (150 mg/kg, once per two weeks) of a intravenous immunoglobulin (IVI) preparation has shown a beneficial effect on CD4/CD8 ratio and CD4 cell counts in two patients with AIDS-related complex (ARC) [26].
Ten patients with hemophilia and HIV infection [8 asymptomatic carriers (AC) and 2 AIDS-related complex (ARC)] were intravenously injected with 1 million IU of IFN-beta twice a week for 6 months [27].

Analytical, diagnostic and therapeutic context of AIDS-Related Complex

Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex [28].
EFFECTIVENESS OF EARLY TREATMENT WITH ZIDOVUDINE: In terms of progression to AIDS-related complex, AIDS or death, clinical trials have not yet shown any long-term benefit for early compared with deferred treatment with zidovudine [29].
Herein are described five patients ultimately diagnosed as having acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) in whom the differential diagnosis included SLE because of multi-system disease and autoimmune phenomena, especially positive antinuclear antibodies [30].
Utility of total body gallium-67 scintigraphy in a patient with AIDS related complex [31].
The level of antibody to AIDS-associated virus (LAV) in sera from patients with AIDS or AIDS related diseases (AIDS related complex; ARC) and Japanese hemophiliacs was studied using indirect immunofluorescence [32].

References

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. Cooley, T.P., Kunches, L.M., Saunders, C.A., Ritter, J.K., Perkins, C.J., McLaren, C., McCaffrey, R.P., Liebman, H.A. N. Engl. J. Med. (1990) [Pubmed]
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. Tausk, F.A., McCutchan, A., Spechko, P., Schreiber, R.D., Gigli, I. J. Clin. Invest. (1986) [Pubmed]
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Broder, S., Yarchoan, R., Collins, J.M., Lane, H.C., Markham, P.D., Klecker, R.W., Redfield, R.R., Mitsuya, H., Hoth, D.F., Gelmann, E. Lancet (1985) [Pubmed]
Plasma viremia in human immunodeficiency virus infection. Coombs, R.W., Collier, A.C., Allain, J.P., Nikora, B., Leuther, M., Gjerset, G.F., Corey, L. N. Engl. J. Med. (1989) [Pubmed]
Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome. Belsito, D.V., Sanchez, M.R., Baer, R.L., Valentine, F., Thorbecke, G.J. N. Engl. J. Med. (1984) [Pubmed]
Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Mildvan, D., Machado, S.G., Wilets, I., Grossberg, S.E. Lancet (1992) [Pubmed]
Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Carter, W.A., Strayer, D.R., Brodsky, I., Lewin, M., Pellegrino, M.G., Einck, L., Henriques, H.F., Simon, G.L., Parenti, D.M., Scheib, R.G. Lancet (1987) [Pubmed]
Rapid, easy, and economical screening test for antibodies to human immunodeficiency virus. Carlson, J.R., Mertens, S.C., Yee, J.L., Gardner, M.B., Watson-Williams, E.J., Ghrayeb, J., Jennings, M.B., Biggar, R.J. Lancet (1987) [Pubmed]
Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. Schmitt, F.A., Bigley, J.W., McKinnis, R., Logue, P.E., Evans, R.W., Drucker, J.L. N. Engl. J. Med. (1988) [Pubmed]
Urinary neopterin and biopterin levels in patients with AIDS and AIDS-related complex. Abita, J.P., Cost, H., Milstien, S., Kaufman, S., Saimot, G. Lancet (1985) [Pubmed]
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Skowron, G., Bozzette, S.A., Lim, L., Pettinelli, C.B., Schaumburg, H.H., Arezzo, J., Fischl, M.A., Powderly, W.G., Gocke, D.J., Richman, D.D., Pottage, J.C., Antoniskis, D., McKinley, G.F., Hyslop, N.E., Ray, G., Simon, G., Reed, N., LoFaro, M.L., Uttamchandani, R.B., Gelb, L.D., Sperber, S.J., Murphy, R.L., Leedom, J.M., Grieco, M.H., Zachary, J., Hirsch, M.S., Spector, S.A., Bigley, J., Soo, W., Merigan, T.C. Ann. Intern. Med. (1993) [Pubmed]
Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Crumpacker, C., Heagy, W., Bubley, G., Monroe, J.E., Finberg, R., Hussey, S., Schnipper, L., Lucey, D., Lee, T.H., McLane, M.F. Ann. Intern. Med. (1987) [Pubmed]
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Kahn, J.O., Allan, J.D., Hodges, T.L., Kaplan, L.D., Arri, C.J., Fitch, H.F., Izu, A.E., Mordenti, J., Sherwin, J.E., Groopman, J.E. Ann. Intern. Med. (1990) [Pubmed]
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Larder, B.A., Kemp, S.D., Purifoy, D.J. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS. Voth, R., Rossol, S., Klein, K., Hess, G., Schütt, K.H., Schröder, H.C., Meyer zum Büschenfelde, K.H., Müller, W.E. J. Immunol. (1990) [Pubmed]
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Knupp, C.A., Shyu, W.C., Dolin, R., Valentine, F.T., McLaren, C., Martin, R.R., Pittman, K.A., Barbhaiya, R.H. Clin. Pharmacol. Ther. (1991) [Pubmed]
Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. Li, R.C., Nightingale, S., Lewis, R.C., Colborn, D.C., Narang, P.K. Antimicrob. Agents Chemother. (1996) [Pubmed]
Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection. Gerna, G., Parea, M., Percivalle, E., Zipeto, D., Silini, E., Barbarini, G., Milanesi, G. AIDS (1990) [Pubmed]
AIDS and antibodies to human immunodeficiency virus (HIV) in children and their families. Martin, K., Katz, B.Z., Miller, G. J. Infect. Dis. (1987) [Pubmed]
AIDS-related complex treated by antiviral drugs and allogeneic bone marrow transplantation following conditioning protocol with busulphan, cyclophosphamide and cyclosporin. Torlontano, G., Di Bartolomeo, P., Di Girolamo, G., Angrilli, F., Verani, P., Maggiorella, M.T., Dragani, A., Iacone, A., Papalinetti, G., Olioso, P. Haematologica (1992) [Pubmed]
Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. van der Wouw, P.A., van Leeuwen, R., van Oers, R.H., Lange, J.M., Danner, S.A. Br. J. Haematol. (1991) [Pubmed]
Thiamine deficiency and Wernicke's encephalopathy in AIDS. Butterworth, R.F., Gaudreau, C., Vincelette, J., Bourgault, A.M., Lamothe, F., Nutini, A.M. Metabolic brain disease. (1991) [Pubmed]
Expression of alpha-fetoprotein and interleukin 2 receptors and impairment of membrane fluidity in peripheral blood mononuclear cells from AIDS and related syndromes. Macho, A., Aguilar, J.J., Naval, J., Girard, P.M., Uriel, J. AIDS Res. Hum. Retroviruses (1994) [Pubmed]
Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Wieland, U., Kühn, J.E., Jassoy, C., Rübsamen-Waigmann, H., Wolber, V., Braun, R.W. Med. Microbiol. Immunol. (Berl.) (1990) [Pubmed]
Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC). Manfredi, R., Vezzadini, P., Fanti, M.P., Chiodo, F. Scand. J. Infect. Dis. (1994) [Pubmed]
Effect of immunoglobulin preparation on course of AIDS-related complex (ARC). Ohno, T., Kanoh, T., Uchino, H., Harada, S. Tohoku J. Exp. Med. (1988) [Pubmed]
Beta-interferon and early stage HIV infection. Oka, S., Hirabayashi, Y., Mouri, H., Sakurada, S., Goto, H., Ohnishi, K., Kimura, S., Mitamura, K., Shimada, K. J. Acquir. Immune Defic. Syndr. (1989) [Pubmed]
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Karpas, A., Hewlett, I.K., Hill, F., Gray, J., Byron, N., Gilgen, D., Bally, V., Oates, J.K., Gazzard, B., Epstein, J.E. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
Future treatment strategies in HIV infection. Dormont, J. AIDS (1994) [Pubmed]
Association of human immunodeficiency virus infection and autoimmune phenomena. Kopelman, R.G., Zolla-Pazner, S. Am. J. Med. (1988) [Pubmed]
Utility of total body gallium-67 scintigraphy in a patient with AIDS related complex. Ford, P.V., Lim, A.B., Abrams, D., Parker, H.G. J. Nucl. Med. (1987) [Pubmed]
Distribution of the level of antibody to AIDS-associated virus (LAV) in sera from AIDS or AIDS related complex and Japanese hemophiliacs infected with AIDS-associated virus. Tsuchie, H., Kawatani, T., Nakayama, E., Matsui, T., Kurimura, T., Hinuma, Y. Microbiol. Immunol. (1985) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.